741290-82-4

Upstream product

• 741290-77-7 tert-butyl (3S)-3-(3-nitrophenoxy)pyrrolidine-1-carboxylate 
• 554-84-7 meta-nitrophenol 
• 109431-87-0 (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate 
• 1193104-13-0 tert-butyl 3-(3-nitrophenoxy)pyrrolidine-1-carboxylate 
• 591-27-5 m-Hydroxyaniline 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 402-67-5 3-fluoro-1-nitrobenzene 

Downstream Products

• 389058-54-2 3-[3-(5-carbamoyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-ylamino)-phenoxy]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 389058-61-1 1,3-dimethyl-4-[3-(pyrrolidin-3-yloxy)-phenylamino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid amide 

Relevant academic research and scientific papers

SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF

The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Pyrimidine derivative, preparation method therefor and application thereof in medicine

The invention relates to a pyrimidine derivative, a preparation method therefor and an application thereof in medicine. Particularly, the invention relates to a compound as shown in general formula (M) or a stereisomer, an aquo-complex, a metabolic product, a solvate, a pharmaceutically acceptable salt, a co-crystallization or a prodrug thereof; the preparation method thereof; and the application of the medicine composition thereof and the compound medicine compound in the medicine, particularly the application as an EGFR target spot inhibitor, wherein the definition of each substituent group in the general formula (M) is the same as that of the specification.

Imidazopyrazines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

New orally active PDE4 inhibitors with therapeutic potential

The design, synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridine derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhib